Low-Dose Systemic Phosphodiesterase III Inhibitor Pimobendan Combined with Prostacyclin Therapy in a Patient with Severe Primary Pulmonary Hypertension

Cardiovascular Drugs and Therapy

Volumn 17, Issue 4, 2003, Pages 375-379

  Watanabe, Eri ^a   Shiga, Tsuyoshi ^a   Matsuda, Naoki ^a   Kajimoto, Katsuya ^a   Naganuma, Miyoko ^a   Kawai, Akihiko ^a   Kasanuki, Hiroshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Phosphodiesterase III; Pimobendan; Primary pulmonary hypertension; Prostacyclin; Right heart failure

Indexed keywords

ACETYLSALICYLIC ACID; BERAPROST; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC AMP; DIGOXIN; FUROSEMIDE; HEPARIN; ILOPROST; MILRINONE; NITRATE; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN; PROSTACYCLIN; SILDENAFIL; SPIRONOLACTONE; TICLOPIDINE;

ADULT; ARTICLE; CASE REPORT; FEMALE; HEART ARRHYTHMIA; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SIDE EFFECT; VASODILATATION; WALKING;

ADULT; DRUG THERAPY, COMBINATION; EPOPROSTENOL; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; PROSTAGLANDINS I; PYRIDAZINES;

EID: 0345059760     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1027328614686     Document Type: Article

References (21)

1. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
2. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-117.
3. Hertz MI, Taylor DO, Trulock EP, et al. The registry of the International Society for Heart and Lung Transplantation: Nineteenth official report-2002. J Heart Lung Transplant 2002;21:950-970.
4. Hinderliter AL, Willis IV PW, Barst RJ, et al. for the Primary Pulmonary Hypertension Study Group. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997;95:1479-1486.
5. Higenbottam T, Spiegelhalter D, Scott JP, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993;70:366-370.
6. Böhm M, Morano I, Pieske B, et al. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res 1991;68:689-701.
7. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994;266:L536-L543.
8. Givertz M, Hare J, Loh E, Gauthier D, Colucci W. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: A rapid test for reversibility of pulmonary hypertension. J Am Coll Cardiol 1996;28:1775-1780.
9. Pamboukian SV, Carere RG, Webb JG, et al. The use of milrinone in pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension. J Heart Lung Transplant 1999;18:367-371.
10. Schermuly RT, Roehl A, Weissmann N, et al. Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001;281:L1361-L1368.
11. Schermuly RT, Ghofrani HA, Enke B, et al. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. Am J Respir Crit Care Med 1999;160:1500-01506.
12. Trophy TJ. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998;157:351-370.
13. Yamazaki Y, Matsumoto H, Takeda A, et al. Effects of pimobendan on pulmonary hypertension in patients with chronic pulmonary emphysema. Nihon Kyobu Shikkan Gakkai Zasshi 1997;35:847-853 (in Japanese with English abstract).
14. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000;343: 1342.
15. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-1222.
16. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515-522.
17. Maisel A. B-Type natriuretic peptide levels: A potential novel "white count" for congestive heart failure. J Card Fail 2001;7:183-193.
18. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31:202-208.
19. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-870.
20. Hayashi H, Nakajima M, Tanahashi Y, et al. Clinical evaluation of pimobendan (UD-CG 115 BS) on acute heart failure - Dose finding study for a multicenter double-blind group comparison-. Ther Res 1992;13:591-612 (in Japanese with English abstract).
21. Ishiki R, Ishihara H, Izawa H, Nagata K, Hirai M, Yokota M. Acute effects of a single low dose of pimobendan on left ventricular systolic and diastolic function in patients with congestive heart failure. J Cardiovasc Pharmacol 2000;35:897-905.